Advertisement

Topics

First Us Fda approval of Car-T therapy hikes expectations for Korean biotech ventures

02:49 EDT 11 Sep 2017 | Topix

The US Food and Drug Administration's first approval of a CAR-T cell therapy is raising market expectations for South Korean biotech ventures that are currently working to develop similar cellular immunotherapy drugs for cancer. On Aug. 30, the US drug regulator approved Novartis' Kymriah, a CAR-T cell therapy that genetically alters a patient's own immune cells into a "living drug" that is trained to recognize and attack cancer cells in the blood.

Original Article: First Us Fda approval of Car-T therapy hikes expectations for Korean biotech ventures

NEXT ARTICLE

More From BioPortfolio on "First Us Fda approval of Car-T therapy hikes expectations for Korean biotech ventures"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...